SEC Form 4 · accession 0001193125-26-359679
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Frates
Officer — Chief Financial Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2026 | A | 22,807 | $0.00 | A | 244,435 | D | |
| Common StockF2 | holding | — | — | — | 100,000 | I | By Trust | |
| Common StockF3 | holding | — | — | — | 15,459 | I | By Trust | |
| Common StockF4 | holding | — | — | — | 11,072 | I | By Trust | |
| Common StockF5,F6 | holding | — | — | — | 40,000 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.
- F2Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F3Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F4Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F5Reflects 40,000 shares previously reported as directly beneficially owned by the Reporting Person, which were transferred to the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1 on August 7, 2026 for no consideration. Such transfer constituted a change in form of beneficial ownership, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
- F6Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.